← Back to IOVA

Iovance Biotherapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 06/08/2026Mar 2026Filed 07/05/2026Sep 2025Filed 06/11/2025Jun 2025Filed 06/08/2026Mar 2025Filed 07/05/2026Sep 2024Filed 06/11/2025Jun 2024Filed 07/08/2025Mar 2024Filed 08/05/2025
$99$71$67$60$49$59$31$0.7
−$47−$79−$91−$112−$116−$84−$97−$113
−$0.11−$0.19−$0.25−$0.33−$0.36−$0.28−$0.34−$0.42

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.